Skip to main content
Reshma Rangwala, MD, Internal Medicine, Saint Louis, MO

Reshma Rangwala MD

Hospital Medicine/Hospitalist, Hematology/Oncology


Physician

Join to View Full Profile
  • 1 Barnes Jewish Hospital PlzSaint Louis, MO 63110

  • Phone+1 314-362-1700

  • Fax+1 314-362-9878

Are you Dr. Rangwala?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Dr. Reshma Rangwala, MD is an internist in Saint Louis, Missouri.

Education & Training

  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2010 - 2013
  • Washington University/B-JH/SLCH Consortium
    Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2006 - 2009
  • University of Cincinnati College of Medicine
    University of Cincinnati College of MedicineClass of 2006

Publications & Presentations

PubMed

Press Mentions

  • Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis
    Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in MyelofibrosisOctober 31st, 2024
  • Karyopharm Announces Presentation of Interim Data from Phase 2 Study of Single-Agent Eltanexor in Relapsed/Refractory (R/R) Higher-Risk Myelodysplastic Neoplasms (MDS) at 17th International Congress on MDS
    Karyopharm Announces Presentation of Interim Data from Phase 2 Study of Single-Agent Eltanexor in Relapsed/Refractory (R/R) Higher-Risk Myelodysplastic Neoplasms (MDS) at 17th International Congress on MDSMay 3rd, 2023
  • Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue and Outlines 2023 Objectives
    Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue and Outlines 2023 ObjectivesJanuary 9th, 2023
  • Join now to see all